Sanofi, Exscientia Join Forces on Drug Development
07 Januar 2022 - 07:51AM
Dow Jones News
By Joshua Kirby
Sanofi SA and Exscientia PLC are to partner on drug development
in oncology and immunology in a deal that could see the latter
receive up to $5.3 billion, the two pharmaceutical companies said
Friday.
Paris-listed Sanofi and U.K.-based Exscientia will collaborate
to identify and select target projects, using Exscientia's
artificial-intelligence-driven personalized medicine platform.
Under the research, collaboration and licensing agreement, the
two companies will develop up to 15 novel small-molecule candidates
in oncology and immunology, they said in a joint release.
Sanofi will pay Exscientia an upfront cash payment of $100
million, while future payments could reach some $5.2 billion,
relating to commercial, clinical and regulatory milestones, the
companies said.
If Sanofi commercializes a therapeutic treatment from the
collaboration, Exscientia will also be eligible to receive tiered
royalties on product sales ranging from a rate of high single
digits to mid-teens, and an option for clinical co-investment to
increase the royalty rate up to 21% on net sales of cofunded
products, the companies said.
Write to Joshua Kirby at joshua.kirby@wsj.com;
@joshualeokirby
(END) Dow Jones Newswires
January 07, 2022 01:36 ET (06:36 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Sanofi (EU:SAN)
Historical Stock Chart
Von Mär 2023 bis Mär 2024